Impedimed gains another trial clinic

Company News

 Impedimed Limited (ASX:IPD) says another world-leading hospital has joined its L-Dex post approval trial. 
 
The L-Dex technology helps physicians and surgeon detect changes in cellular fluid levels to detect lymphadema post-surgery. 
 
The prestigious Mayo Clinic in Jacksonville Florida has now joined the list of National Cancer Institute of cancer centres in the international trial. 
 
Impedimed reported a net loss of $6.1 million for the full year ending 31 December 2014. 

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.